Skip to main content
. Author manuscript; available in PMC: 2016 Aug 3.
Published in final edited form as: J Am Geriatr Soc. 2015 Aug 3;63(8):1512–1518. doi: 10.1111/jgs.13511

Table 2. Characteristics Of Propensity Score Matched Cohort, All Matched Subjects, N = 3,377.

Characteristic Cholinesterase Inhibitor New User N = 1,188 Non-Cholinesterase New User N = 2,189 p-value
Age, mean (± SD) 77.9 (6.2) 77.7 (6.8) 0.38
Male, n (%) 1159 (97.6) 2136 (97.6) 0.97
Race, n (%)
 White, non Hispanic 883 (74.3) 1663 (76.0)
 Black, non Hispanic 197 (16.6) 374 (17.1)
 Hispanic 64 (5.4) 76 (3.5) 0.09
 Asian 14 (1.2) 19 (0.9)
 Other 30 (2.5) 57 (2.6)
Number of Comorbid Conditions, mean (± SD) 3.1 (2.1) 3.1 (2.1) 0.86
 Cerebrovascular Accident, n (%) 135 (11.4) 264 (12.1) 0.55
 COPD/Asthma, n (%) 158 (13.3) 317 (14.5) 0.35
 Hypertension, n (%) 824 (69.4) 1476 (67.4) 0.25
 Hyperlipidemia, n (%) 505 (42.5) 913 (41.7) 0.65
 Diabetes Mellitus, n (%) 341 (28.7) 645 (29.5) 0.64
 Gastroesophageal Reflux Disease, n (%) 144 (12.1) 288 (13.2) 0.39
 Depression, n (%) 209 (17.6) 388 (17.7) 0.92
 Atrial Fibrillation, n (%) 119 (10.0) 200 (9.1) 0.40
Number of chronic medications, mean (± SD) 9.7 (5.7) 9.9 (5.4) 0.40
Prescribed Memantine, n (%) 46 (3.9) 68 (3.1) 0.24
Hospitalized in past year, n (%) 336 (28.3) 635 (29.0) 0.66
Number of outpatient visits in baseline year, median [IQR] 6 (4, 9) 6 (3, 9) 0.06
Baseline weight in pounds, mean (± SD) 174.9 (32.8) 176.7 (34.5) 0.12
Frequency of weight measures in year prior, n (%)
 2-5 398 (33.5) 793 (36.2)
 6-10 499 (42.0) 841 (38.4) 0.11
 ≥ 11 291 (24.5) 555 (25.4)
Weight trajectory in year prior in pounds, mean (± SD) 0.9 (4.8) 0.8 (5.0) 0.59